On October 19, 2009
Why Estimates of Future Revenues for Obesity Drugs Are Likely Off the Mark
The total annual revenue for all obesity drugs is just $173 million in the United States. So why do people believe that Vivus, Arena and Orexigen will generate $1 billion to $10 billion with their as-yet unapproved drugs?
0 Comments